Photodegraded Edible Food Dyes
NCT04708704 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2022-11-01
Summary
Assess and contrast the effect of erythrosine and photodegraded erythrosine on thyroid function. Thyroid function will be evaluated as serum triiodothyronine (T3), thyroxine (T4), thyroid stimulating hormone (TSH), T3 resin uptake as well as measures of iodine in serum and plasma before and after a 14-day repeat administration of these edible dyes in drinking water. Dose-related increases in serum and plasma-bound iodine are expected for both erythrosine and photodegraded erythrosine over the 14-day exposure period. TSH is also expected to increase following repeat administration of erythrosine and photodegraded erythrosine. Erythrosine and photodegraded erythrosine are expected to induce an equivalent dose-response increase in thyroid function-related hormone levels.
Conditions
- Thyroid; Functional Disturbance
Interventions
- DIETARY_SUPPLEMENT
-
Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)
Erythrosine will be obtained from Roxy \& Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
- DIETARY_SUPPLEMENT
-
SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)
Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with \~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
- DIETARY_SUPPLEMENT
-
Iodine, prepared in drinking water 0.075 mg/kg bw/day)
Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
Sponsors & Collaborators
-
Yale University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-09-01
- Primary Completion
- 2023-12-31
- Completion
- 2024-12-31
Countries
- United States
Study Locations
More Related Trials
-
Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment
NCT01739972 ·Status: UNKNOWN ·Phase: NA
-
Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets
NCT01465633 ·Status: COMPLETED ·Phase: PHASE1
-
DIM as a Treatment for Thyroid Disease
NCT01846364 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism
NCT05733078 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects
NCT01581463 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants
NCT02024906 ·Status: WITHDRAWN ·Phase: NA
-
Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients
NCT04747275 ·Status: TERMINATED ·Phase: PHASE4
-
Preoperative Administration of Lugols Solution in Toxic Thyroid Diseases (TD): A Prospective Study
NCT06176976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Serum Thyroglobulin as a Marker of Iodine Status During Pregnancy
NCT02927119 ·Status: COMPLETED
-
A Study of T3 Therapy in Patients With Hypothyroidism
NCT01800617 ·Status: COMPLETED ·Phase: PHASE2
-
Thyroid Study Type 2 Diabetes Mellitus (T2DM)
NCT01379170 ·Status: UNKNOWN ·Phase: PHASE4
-
Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)
NCT05228184 ·Status: TERMINATED ·Phase: PHASE4
-
Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant
NCT02378233 ·Status: TERMINATED ·Phase: NA
-
Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
NCT07239674 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
The Effect of Iodine Intakes on Maternal and Infant Health and the Study of Iodine RNI for Different Stages of Pregnancy
NCT03710148 ·Status: UNKNOWN
-
Selenium Supplementation in Pregnancy
NCT01465867 ·Status: COMPLETED ·Phase: NA
-
A Study of E7080 in Subjects With Advanced Thyroid Cancer
NCT01728623 ·Status: COMPLETED ·Phase: PHASE2
-
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
NCT04348513 ·Status: TERMINATED ·Phase: PHASE2
-
Iontophoresis With Potassium Iodide and Thyroid Function
NCT04013308 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
NCT02278198 ·Status: COMPLETED ·Phase: PHASE1
-
EUthyroid2: the Next Step Towards the Elimination of Iodine Deficiency and Preventable Iodine-related Disorders in Europe
NCT06769009 ·Status: RECRUITING ·Phase: NA
-
Iodine-129 Tracer Method for Investigating Human Iodine Metabolism
NCT02955745 ·Status: COMPLETED
-
Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules
NCT03535974 ·Status: COMPLETED ·Phase: NA
-
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
NCT06405217 ·Status: RECRUITING ·Phase: NA
-
Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain
NCT00237523 ·Status: UNKNOWN ·Phase: PHASE3